These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W. Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [Abstract] [Full Text] [Related]
12. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650 [Abstract] [Full Text] [Related]
13. Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies. Park SJ, Min WS, Yang IH, Kim HJ, Min CK, Eom HS, Kim DW, Han CW, Lee JW, Kim CC. Korean J Intern Med; 2000 Dec; 15(3):224-31. PubMed ID: 11242811 [Abstract] [Full Text] [Related]
14. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW. Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437 [Abstract] [Full Text] [Related]
15. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, Cahn JY, Passweg JR, Rowlings PA, Schouten HC, Kolb HJ, Klein JP. N Engl J Med; 1999 Jul 01; 341(1):14-21. PubMed ID: 10387937 [Abstract] [Full Text] [Related]
17. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, Sok A, Drabczak-Skrzypek D, Sedzimirska M, Lange A. Transplant Proc; 2007 Nov 01; 39(9):2898-901. PubMed ID: 18022011 [Abstract] [Full Text] [Related]
18. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J, Ringdén O. Clin Transplant; 1994 Jun 01; 8(3 Pt 1):258-70. PubMed ID: 8061365 [Abstract] [Full Text] [Related]
19. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF. Leukemia; 2002 Aug 01; 16(8):1423-31. PubMed ID: 12145680 [Abstract] [Full Text] [Related]
20. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Gale RP, Horowitz MM. Bone Marrow Transplant; 1990 Jul 01; 6 Suppl 1():94-7. PubMed ID: 2390646 [Abstract] [Full Text] [Related] Page: [Next] [New Search]